摘要
阿尔茨海默病(AD)是一种退行性脑功能障碍疾病,是痴呆症最常见的类型。用结合生物标志物的微创的方法来确认有风险患轻度认知障碍(MCI)和AD的患者,合适地有针对性地发现治疗的临床试验以及预防此病的生活方式的策略。对澳大利亚人群进行口腔黏膜细胞影像,生物标志物和老龄化群体(n = 60)的生活方式的旗舰研究中,细胞学标记可用于识别MCI和AD患者。口腔细胞组的视觉评分显示,与对照组相比,MCI组有显著低频率的基底核细胞。利用激光扫描细胞仪开发出高含量的自动检测,同时测量口腔黏膜细胞的细胞类型、核DNA含量和非整倍性、中性脂质含量,公认的tau蛋白和β淀粉样蛋白(Aβ)。各组有相似的DNA含量、染色体非整倍体,中性脂肪和tau蛋白。然而,与分化的口腔细胞相比,在基底和溶核的口腔细胞类型里有显著降低的tau蛋白。AD组包含β淀粉样蛋白信号,以及包含β淀粉样蛋白信号的区域和积分的细胞频率明显高于对照组。口腔细胞的β淀粉样蛋白与简易精神状态检查(MMSE)评分(r=-0.436,P = 0.001)和血液中的生物标志物呈正相关。结合口腔细胞里新确定的与那些已经明确的生物标志物可能为更具体的生物标志物的面板提供可能的途径,会大大增加为AD早期诊断提供更好的预测指标的可能性。
关键词: 阿尔茨海默病、淀粉样蛋白、口腔细胞、脱氧核糖核酸含量、激光扫描式细胞仪、轻度认知功能障碍、中性脂质。
Current Alzheimer Research
Title:High Content, Multi-Parameter Analyses in Buccal Cells to Identify Alzheimer’s Disease
Volume: 13 Issue: 7
Author(s): Maxime François, Michael F. Fenech, Philip Thomas, Maryam Hor, Alan Rembach, Ralph N. Martins, Stephanie R. Rainey-Smith, Colin L. Masters, David Ames, Christopher C. Rowe, S. Lance Macaulay, Andrew F. Hill, Wayne R. Leifert and The Australian Imaging and Biomarkers, Lifestyle Study Research Group
Affiliation:
关键词: 阿尔茨海默病、淀粉样蛋白、口腔细胞、脱氧核糖核酸含量、激光扫描式细胞仪、轻度认知功能障碍、中性脂质。
摘要: Alzheimer’s disease (AD) is a degenerative brain disorder and is the most common form of dementia. Minimally invasive approaches are required that combine biomarkers to identify individuals who are at risk of developing mild cognitive impairment (MCI) and AD, to appropriately target clinical trials for therapeutic discovery as well as lifestyle strategies aimed at prevention. Buccal mucosa cells from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing cohort (n=60) were investigated for cytological markers that could be used to identify both MCI and AD individuals. Visual scoring of the buccal cytome demonstrated a significantly lower frequency of basal and karyorrhectic cells in the MCI group compared with controls. A high content, automated assay was developed using laser scanning cytometry to simultaneously measure cell types, nuclear DNA content and aneuploidy, neutral lipid content, putative Tau and amyloid-β (Aβ) in buccal cells. DNA content, aneuploidy, neutral lipids and Tau were similar in all groups. However, there was significantly lower Tau protein in both basal and karyolytic buccal cell types compared with differentiated buccal cells. Aβ, as measured by frequency of cells containing Aβ signal, as well as area and integral of Aβ signal, was significantly higher in the AD group compared with the control group. Buccal cell Aβ was correlated with mini-mental state examination (MMSE) scores (r = -0.436, P=0.001) and several blood-based biomarkers. Combining newly identified biomarkers from buccal cells with those already established may offer a potential route for more specific biomarker panels which may substantially increase the likelihood of better predictive markers for earlier diagnosis of AD.
Export Options
About this article
Cite this article as:
Maxime François, Michael F. Fenech, Philip Thomas, Maryam Hor, Alan Rembach, Ralph N. Martins, Stephanie R. Rainey-Smith , Colin L. Masters, David Ames, Christopher C. Rowe, S. Lance Macaulay, Andrew F. Hill, Wayne R. Leifert and The Australian Imaging and Biomarkers, Lifestyle Study Research Group , High Content, Multi-Parameter Analyses in Buccal Cells to Identify Alzheimer’s Disease, Current Alzheimer Research 2016; 13 (7) . https://dx.doi.org/10.2174/1567205013666160315112151
DOI https://dx.doi.org/10.2174/1567205013666160315112151 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Acetylcholinesterase Inhibitors in the Metabolism of Amyloid Precursor Protein
Current Drug Targets - CNS & Neurological Disorders New Developments in Anti-Platelet Therapies Potential Use of CD39/Vascular ATP Diphosphohydrolase in Thrombotic Disorders
Current Drug Targets COVID-19-associated Coagulopathy and Thromboembolism: Determination of Their Patterns and Risk Factors as Predictors of Mortality Among Severe COVID-19 Patients
Current Vascular Pharmacology Progranulin Mutations in Ubiquitin-Positive Frontotemporal Dementia Linked to Chromosome 17q21
Current Alzheimer Research Pleasure as an Overlooked Target of Substance Use Disorder Research and Treatment
Current Drug Abuse Reviews Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research Lagenaria siceraria: A Potential Source of Anti-Hyperlipidemic and Other Pharmacological Agents
Current Nutrition & Food Science Defining Dystonic Tremor
Current Neuropharmacology Leptin Induces Neuroprotection Neurogenesis and Angiogenesis after Stroke
Current Neurovascular Research Bromelain Degrades Aβ1-42 Monomers and Soluble Aggregates: An In Vitro Study in Cerebrospinal Fluid of Alzheimer’s Disease Patients
Current Alzheimer Research Tau, Amyloid Beta and Deep Brain Stimulation: Aiming to Restore Cognitive Deficit in Alzheimer's Disease
Current Alzheimer Research Detour Cum Distance Matrix Based Topological Descriptors for QSAR/QSPR Part-II: Application in Drug Discovery Process
Letters in Drug Design & Discovery Kinetic Study on the Effects of Extremely Low Frequency Electromagnetic Field on Catalase, Cytochrome P450 and Inducible Nitric Oxide Synthase in Human HaCaT and THP-1 Cell Lines
CNS & Neurological Disorders - Drug Targets Genetic Risk Factors in Cerebrovascular Disorders and Cognitive Deterioration
Current Genomics Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder
Current Neuropharmacology Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology GSK-3 Inhibitors: A New Class of Drugs for Alzheimer’s Disease Treatment
Current Drug Targets Amyloid Formation in Surfactants and Alcohols: Membrane Mimetics or Structural Switchers?
Current Protein & Peptide Science An Exposition of <sup>11</sup>C and <sup>18</sup>F Radiotracers Synthesis for PET Imaging
Current Radiopharmaceuticals Therapy of XDR TB with Thioridazine a Drug Beyond Patent Protection but Eligible for Patent “As New Use”
Recent Patents on Anti-Infective Drug Discovery